WuXi AppTec Co., Ltd. (WUXIF)
OTCMKTS
· Delayed Price · Currency is USD
7.34
0.00 (0.00%)
May 16, 2025, 4:00 PM EDT
WuXi AppTec Revenue
WuXi AppTec had revenue of 9.65B CNY in the quarter ending March 31, 2025, with 20.96% growth. This brings the company's revenue in the last twelve months to 39.59B, up 5.03% year-over-year. In the year 2024, WuXi AppTec had annual revenue of 37.92B, down -1.97%.
Revenue (ttm)
39.59B CNY
Revenue Growth
+5.03%
P/S Ratio
4.53
Revenue / Employee
1.00M CNY
Employees
39,414
Market Cap
24.74B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 37.92B | -760.22M | -1.97% |
Dec 31, 2023 | 38.68B | -676.78M | -1.72% |
Dec 31, 2022 | 39.35B | 16.45B | 71.84% |
Dec 31, 2021 | 22.90B | 6.37B | 38.50% |
Dec 31, 2020 | 16.54B | 3.66B | 28.46% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
WuXi AppTec News
- 21 days ago - WuXi AppTec Co., (WUXIF) Ltd. Q1 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY - PRNewsWire
- 4 weeks ago - WuXi Group Wrestles With Uncertainty Over Pharma Tariffs - Benzinga
- 7 weeks ago - WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections - PRNewsWire
- 2 months ago - WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs - PRNewsWire
- 4 months ago - WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI) - PRNewsWire
- 5 months ago - WuXi AppTec's Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year - PRNewsWire
- 6 months ago - WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating - PRNewsWire